Please assess the completion status of the following clinical trial:

Trial Title: A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine in a Pediatric Population

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male or non-pregnant female participants aged ≥ 6 calendar months to \< 18 years at the time of the first study vaccination.~* For participants aged ≥ 6 months to \< 9 years, born after a normal gestation period (between 36 and 42 weeks).~* Females of childbearing potential (i.e., ovulating, pre-menopausal, not surgically sterile) must be abstinent or be willing to use a medically accepted contraceptive regimen for at least 2 months after vaccination. Females aged ≥ 9 years must also return a negative urine pregnancy test at enrollment.~Exclusion Criteria:~* Known hypersensitivity to a previous dose of influenza vaccine or allergy to eggs, chicken protein, neomycin, polymyxin, or any components of the Study Vaccine.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 17 Years
- Healthy Volunteers: t

Study Arms:
- Afluria Cohort A (Type: EXPERIMENTAL): Age 6 months to \< 3 years
- Afluria Cohort B (Type: EXPERIMENTAL): Age 3 to \< 9 years
- Afluria Cohort C (Type: EXPERIMENTAL): Age 9 to \< 18 years
- Fluzone Cohort A (Type: ACTIVE_COMPARATOR): Age 6 months to \< 3 years
- Fluzone Cohort B (Type: ACTIVE_COMPARATOR): Age 3 to \< 9 years
- Fluzone Cohort C (Type: ACTIVE_COMPARATOR): Age 9 to \< 18 years

Based on this trial design, predict the completion outcome and termination type (if applicable).